Sun Pharma's Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg in Active Psoriatic Arthritis Meet their Primary Endpoint

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA®) administered over 24 weeks for treatment of active psoriatic arthritis.

Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05).

"We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future," said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.

Safety data in the studies was consistent with the well-documented safety profile of ILUMYA, which is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. No new safety signals were identified in the INSPIRE-1 and INSPIRE-2 studies.

Findings from the INSPIRE studies will be presented at upcoming medical conferences and published in a peer-reviewed medical journal. Use of tildrakizumab 100 mg (ILUMYA) in psoriatic arthritis is not approved, and its safety and efficacy have not been evaluated by regulatory authorities.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1692.10 as compared to the previous close of Rs. 1682.60. The total number of shares traded during the day was 160759 in over 2194 trades.

The stock hit an intraday high of Rs. 1695.00 and intraday low of 1680.00. The net turnover during the day was Rs. 271412162.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 ToplineResults Phase3 ClinicalStudies tildrakizumab 100mg